Kymera Therapeutics, Inc. (KYMR)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$111.95−$3.86 (−3.33%) on the dayAs of the close; data may be delayed.
KYMR price, last 12 months
Key stats
- Previous close
- $115.81
- Open
- $115.99
- Day range
- $111.42 – $116.20
- 52-week range
- $51.47 – $130.05
- Volume
- 546.7K
- Avg volume (20 days)
- 730.6K
- Market cap
- $9.3B
Performance
1W−4.9%
1M−10.8%
3M+3.5%
6M+39.6%
YTD+43.9%
1Y+113.2%
vs S&P 500, 1Y+96.5 pts
Technicals and fundamentals
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $9.3B